Pertuzumab combined with trastuzumab plus chemotherapy adds approximately 16 months to median overall survival times for patients with HER2-positive metastatic breast cancer

At ESMO 2014, Prof Sandra Swain presents the results of the CLEOPATRA trial. This phase III trial in patients with HER2-positive metastatic breast cancer showed that treatment with pertuzumab combined with trastuzumab plus docetaxel (pertuzumab group) significantly improved overall survival versus placebo combined with trastuzumab plus docetaxel treatment (control group). Median overall survival in the pertuzumab group was increased by 15.7 months versus the control group.